GO:0045766 positive regulation of angiogenesis: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045766 (positive regulation of angiogenesis) describes any process that activates or increases angiogenesis, the formation of new blood vessels from pre-existing ones.
• Key positive regulators include VEGFR2 (KDR), VEGFA, OPN3, Rap1, and p73, which promote endothelial cell proliferation, migration, and tube formation.
• Negative regulators such as soluble VEGFR-1 (sFlt-1) and certain microRNAs counterbalance pro-angiogenic signals, and their dysregulation contributes to disease.
• Angiogenesis is essential in development, wound healing, and bone regeneration, but excessive or insufficient angiogenesis underlies cancer, cardiovascular disease, and chronic inflammatory disorders.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of pro-angiogenic genes and validation of therapeutic targets.
• EDITGENE provides end-to-end services for angiogenesis research, including custom cell model generation, CRISPR library screening, and bioinformatics analysis.
Description
Angiogenesis, the sprouting of new capillaries from existing vasculature, is a tightly controlled process essential for embryonic development, tissue repair, and reproduction. The Gene Ontology term GO:0045766, positive regulation of angiogenesis, captures any molecular event that activates or increases this process, encompassing pro-angiogenic growth factors, receptors, intracellular signaling cascades, and microenvironmental cues. Dysregulated angiogenesis is a hallmark of numerous pathologies, including tumor progression, diabetic retinopathy, and ischemic cardiovascular disease, making its positive regulation a central focus of biomedical research. Understanding the mechanisms that drive angiogenesis is critical for developing targeted therapies that either promote vessel growth in ischemic tissues or inhibit it in tumors and inflammatory disorders. This article integrates authoritative GO annotations with published literature to provide a comprehensive overview of the genes, pathways, and experimental models used to study positive regulation of angiogenesis.
positive regulation of angiogenesis At A Glance
| GO ID | GO:0045766 |
|---|---|
| GO term | positive regulation of angiogenesis |
| Ontology | biological_process |
| Synonym | activation of angiogenesis, stimulation of angiogenesis, up regulation of angiogenesis, up-regulation of angiogenesis, upregulation of angiogenesis |
| Major function | Activates or increases angiogenesis, the formation of new blood vessels from pre-existing ones |
| Related processes | VEGF signaling, endothelial cell proliferation, migration, tube formation, vascular permeability |
| Key regulators | VEGFA, VEGFR2 (KDR), OPN3, Rap1, p73, microRNAs, HDL |
| Disease relevance | Cancer, cardiovascular disease, bone regeneration, inflammatory disorders |
What Is GO:0045766?
According to the Gene Ontology, GO:0045766 (positive regulation of angiogenesis) is defined as any process that activates or increases the frequency, rate, or extent of angiogenesis. This biological process includes the actions of pro-angiogenic growth factors, their receptors, intracellular signaling molecules, and transcription factors that collectively stimulate endothelial cell proliferation, migration, and tube formation. It is distinct from negative regulation (GO:0016525) and encompasses both direct molecular interactions and indirect pathways that amplify angiogenic signaling.
Why Is positive regulation of angiogenesis Important in Cell Biology?
Positive regulation of angiogenesis is fundamental to both normal physiology and disease pathogenesis. In development and tissue repair, timely activation of angiogenesis ensures adequate oxygen and nutrient supply. In cancer, tumor cells often hijack pro-angiogenic pathways to sustain growth and metastasis, making these pathways prime therapeutic targets. Conversely, insufficient angiogenesis contributes to ischemic heart disease, stroke, and chronic wounds. Understanding the molecular players that positively regulate angiogenesis is therefore essential for designing interventions that either block or enhance vessel growth in a context-dependent manner.
• Drives embryonic development and organogenesis by establishing functional vasculature.
• Supports wound healing and tissue regeneration, including bone repair.
• Promotes tumor growth and metastasis by supplying oxygen and nutrients to cancer cells.
• Contributes to inflammatory diseases such as rheumatoid arthritis and psoriasis.
• Is dysregulated in diabetic retinopathy and age-related macular degeneration.
• Plays a role in cardiovascular repair after myocardial infarction.
• Serves as a target for anti-angiogenic cancer therapies (e.g., anti-VEGF antibodies).
• Involves microRNAs that fine-tune angiogenic responses in bone regeneration.
• Requires tight balance with negative regulators to prevent vascular malformations.
• Offers opportunities for CRISPR-based functional genomics to identify novel pro-angiogenic genes.
What Happens During positive regulation of angiogenesis?
Initiation by pro-angiogenic growth factors
In simple terms: Pro-angiogenic factors like VEGF bind to receptors on endothelial cells and start the process.
Positive regulation of angiogenesis typically begins with the release of pro-angiogenic growth factors such as vascular endothelial growth factor (VEGF) from hypoxic tissues or tumor cells. VEGF binds to VEGFR2 (KDR) on endothelial cells, triggering receptor dimerization and autophosphorylation. This initial activation is amplified by co-receptors like neuropilin and integrins, and can be modulated by soluble decoy receptors such as soluble VEGFR-1 (sFlt-1) that sequester VEGF. The balance between pro- and anti-angiogenic signals determines whether angiogenesis proceeds.
Intracellular signaling cascades
In simple terms: Inside the cell, a relay of signals turns on genes and changes cell behavior.
Upon VEGFR2 activation, downstream pathways including PLCγ-ERK, PI3K-AKT, and Src-FAK are engaged, leading to endothelial cell proliferation, survival, and migration. The small GTPase Rap1 is a critical regulator of endothelial cell adhesion and migration during angiogenesis, acting downstream of growth factor receptors. OPN3, a photoreceptor-like protein, positively regulates angiogenesis in HUVECs through interaction with VEGFR2, enhancing VEGFR2 phosphorylation and downstream signaling. These signaling events converge on transcription factors such as NF-κB and HIF-1α, which induce expression of pro-angiogenic genes.
Endothelial cell activation and tube formation
In simple terms: Endothelial cells multiply, move, and organize into new tube-like structures.
Activated endothelial cells degrade the basement membrane via matrix metalloproteinases, migrate into the surrounding matrix, and proliferate to form sprouts. Tip cells guide the sprout, while stalk cells proliferate and form the lumen. Cell-cell adhesion molecules (VE-cadherin) and integrins mediate tube formation and stabilization. Positive regulators such as p73 can influence this step by modulating endothelial cell survival and migration. The process culminates in the formation of a functional capillary network that is stabilized by pericytes and smooth muscle cells.
Modulation by microRNAs and lipoproteins
In simple terms: Small RNAs and HDL particles can fine-tune how strongly angiogenesis is turned on.
MicroRNAs (miRNAs) are key post-transcriptional regulators of angiogenesis; for example, miR-210, miR-126, and miR-17-92 cluster members promote angiogenesis by targeting negative regulators or enhancing pro-angiogenic signaling. High-density lipoproteins (HDL) also regulate angiogenesis, with studies showing that HDL can stimulate endothelial cell migration and tube formation via SR-BI and S1P receptors. These modulators add layers of complexity to the positive regulation of angiogenesis, integrating metabolic and inflammatory cues.
Crosstalk with negative regulators
In simple terms: There are brakes as well as accelerators, and the balance decides the outcome.
Positive regulation of angiogenesis is counterbalanced by negative regulators such as soluble VEGFR-1 (sFlt-1), thrombospondin-1, and endostatin. sFlt-1 acts as a decoy receptor for VEGF and PlGF, reducing their bioavailability and dampening angiogenic signaling. The relative abundance of pro- and anti-angiogenic factors determines the angiogenic switch, a critical event in tumor progression and other diseases. Understanding this balance is essential for therapeutic manipulation of angiogenesis.
Key Genes Involved in GO:0045766 positive regulation of angiogenesis
The following genes and proteins are central to the positive regulation of angiogenesis, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Primary pro-angiogenic growth factor; binds VEGFR2 to initiate signaling | Target for anti-angiogenic therapy; biomarker in cancer and cardiovascular disease |
| KDR (VEGFR2) | Receptor tyrosine kinase mediating VEGF-induced endothelial cell activation | Key therapeutic target; mutations affect angiogenesis |
| OPN3 | Enhances VEGFR2 phosphorylation and downstream signaling in HUVECs | Novel positive regulator; potential target in vascular disorders |
| RAP1A | Small GTPase regulating endothelial cell adhesion and migration | Modulates angiogenesis downstream of growth factors |
| TP73 (p73) | Transcription factor with context-dependent pro-angiogenic roles | Dual regulator; implicated in tumor angiogenesis |
| FLT1 (VEGFR1) | Decoy receptor; soluble form (sFlt-1) negatively regulates angiogenesis | Biomarker in preeclampsia; target for modulating angiogenesis |
| HIF1A | Hypoxia-inducible factor; induces VEGFA and other pro-angiogenic genes | Central to hypoxia-driven angiogenesis in tumors |
| MMP2 | Matrix metalloproteinase; degrades ECM to allow endothelial sprouting | Promotes invasion and angiogenesis in cancer |
| MMP9 | Matrix metalloproteinase; facilitates endothelial cell migration | Associated with tumor progression and inflammation |
| CDH5 (VE-cadherin) | Endothelial cell-cell adhesion molecule; essential for tube formation | Required for vascular integrity; target in vascular leakage |
| ITGB1 (Integrin β1) | Mediates endothelial cell-matrix adhesion during sprouting | Modulates angiogenesis; potential therapeutic target |
| PECAM1 (CD31) | Endothelial cell adhesion molecule; involved in migration and signaling | Marker of endothelial cells; functional role in angiogenesis |
| NOS3 (eNOS) | Endothelial nitric oxide synthase; produces NO to promote vasodilation and angiogenesis | Regulates vascular tone and angiogenesis |
| SR-BI (SCARB1) | HDL receptor; mediates HDL-induced angiogenesis | Links lipid metabolism to angiogenesis |
| MIR210 | Hypoxia-induced microRNA; promotes angiogenesis | Potential therapeutic target in ischemic disease |
| MIR126 | Endothelial-specific microRNA; enhances VEGF signaling | Biomarker and therapeutic candidate |
| MIR17HG | miR-17-92 cluster; promotes angiogenesis by targeting anti-angiogenic factors | Oncogenic miRNA cluster in cancer |
| SPHK1 | Sphingosine kinase 1; produces S1P, a pro-angiogenic lipid mediator | Modulates HDL effects on angiogenesis |
How Is positive regulation of angiogenesis Regulated?
Positive regulation of angiogenesis is controlled at multiple levels, including transcriptional activation of pro-angiogenic genes by HIF-1α under hypoxia, post-transcriptional modulation by microRNAs such as miR-210 and miR-126, and post-translational modifications of VEGFR2 and downstream effectors. The small GTPase Rap1 integrates signals from growth factor receptors to control endothelial cell adhesion and migration. Soluble decoy receptors like sFlt-1 provide an additional layer of negative feedback to prevent excessive angiogenesis. This multilayered regulation ensures that angiogenesis is activated only when needed and is tightly balanced with anti-angiogenic signals.
positive regulation of angiogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFA | Cancer, ischemic heart disease | VEGFA knockout or overexpression in endothelial cells; tumor xenograft models |
| KDR (VEGFR2) | Cancer, vascular anomalies | KDR knockout mice; point mutations in kinase domain; HUVEC models |
| FLT1 (sFlt-1) | Preeclampsia, cancer | sFlt-1 overexpression in trophoblasts; knockout of membrane Flt1 |
| OPN3 | Vascular disorders | OPN3 knockout HUVECs; VEGFR2 interaction studies |
| MIR210 | Bone regeneration, ischemia | miR-210 knockout or overexpression in osteoblasts/endothelial cells |
Cancer
Tumors require a blood supply to grow beyond a few millimeters, and they often upregulate pro-angiogenic factors such as VEGF to induce angiogenesis. Positive regulation of angiogenesis is therefore a hallmark of cancer, and anti-angiogenic therapies targeting VEGF or VEGFR2 are used in various malignancies. However, resistance to anti-angiogenic therapy can emerge through alternative pro-angiogenic pathways, highlighting the need to understand the full spectrum of positive regulators.
Cardiovascular disease and ischemia
Insufficient angiogenesis contributes to ischemic heart disease, peripheral artery disease, and chronic wounds. Therapeutic angiogenesis aims to stimulate new vessel growth by delivering pro-angiogenic factors or genes, but clinical success has been limited. Understanding positive regulation of angiogenesis is critical for developing effective strategies to promote revascularization.
Bone regeneration and repair
Angiogenesis is essential for bone regeneration, as new blood vessels supply oxygen and nutrients to the forming bone. MicroRNAs such as miR-210 and miR-126 positively regulate angiogenesis in bone regeneration, and their dysregulation can impair fracture healing. Targeting these microRNAs or their downstream pathways may enhance bone repair.
Inflammatory and metabolic disorders
Chronic inflammation often accompanies pathological angiogenesis, as seen in rheumatoid arthritis and psoriasis. High-density lipoproteins (HDL) can modulate angiogenesis, linking lipid metabolism to vascular biology. Dysregulated positive regulation of angiogenesis also contributes to diabetic retinopathy and age-related macular degeneration.
From positive regulation of angiogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X promote angiogenesis? | Knockout of gene X in HUVECs or zebrafish; tube formation assay |
| Does a specific point mutation in VEGFR2 affect its pro-angiogenic activity? | Point-mutation knock-in in HUVECs or mice; phospho-VEGFR2 Western blot |
| Can a tagged version of OPN3 reveal its interaction with VEGFR2? | Knock-in of epitope-tagged OPN3; co-immunoprecipitation |
| Does overexpression of miR-210 enhance angiogenesis in bone regeneration? | Overexpression of miR-210 in mesenchymal stem cells; in vivo bone defect model |
| What is the role of Rap1 in endothelial cell migration? | Rap1 knockout or dominant-negative mutants in endothelial cells; migration assay |
| Can CRISPR library screening identify novel pro-angiogenic genes? | Genome-wide CRISPR knockout library in HUVECs under angiogenic stimulation; next-generation sequencing |
How to Study the positive regulation of angiogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Tube formation assay | Ability of endothelial cells to form capillary-like structures | In vitro assessment of pro-angiogenic factors or gene knockdown |
| Matrigel plug assay | In vivo angiogenesis in a matrix plug | Evaluation of pro-angiogenic compounds or gene function |
| Zebrafish intersegmental vessel formation | Angiogenic sprouting in vivo | Genetic screens and gene function studies |
| Western blot | Protein expression and phosphorylation status | Analysis of VEGFR2 signaling and downstream effectors |
| RNA-seq | Transcriptional changes during angiogenesis | Identification of pro-angiogenic gene signatures |
| microRNA profiling | Expression levels of microRNAs | Discovery of angiogenic microRNAs |
| CRISPR knockout screen | Genes required for angiogenesis | Unbiased discovery of positive regulators |
| Immunoprecipitation | Protein-protein interactions | Validation of OPN3-VEGFR2 interaction |
Endothelial cell tube formation assay
The tube formation assay is a widely used in vitro method to assess angiogenesis. Endothelial cells (e.g., HUVECs) are seeded on a basement membrane matrix, and their ability to form capillary-like tubes is quantified. This assay is used to evaluate the effects of gene knockout, overexpression, or pharmacological agents on positive regulation of angiogenesis.
In vivo angiogenesis models
In vivo models such as the chick chorioallantoic membrane (CAM) assay, Matrigel plug assay, and zebrafish intersegmental vessel formation are used to study angiogenesis in a physiological context. These models allow assessment of pro-angiogenic gene function and validation of therapeutic targets.
Molecular profiling and signaling analysis
Western blotting, immunoprecipitation, and phospho-proteomics are used to dissect signaling pathways downstream of pro-angiogenic receptors. RNA-seq and microRNA profiling identify transcriptional and post-transcriptional changes during angiogenesis. These methods help pinpoint key nodes in positive regulation of angiogenesis.
CRISPR-based functional genomics
CRISPR knockout and activation screens enable unbiased discovery of genes that positively regulate angiogenesis. Pooled libraries targeting the genome can be introduced into endothelial cells, followed by selection under angiogenic conditions and next-generation sequencing to identify enriched or depleted sgRNAs. This approach has identified novel regulators such as OPN3.
How CRISPR Can Be Used to Study GO:0045766 positive regulation of angiogenesis
Knockout
CRISPR knockout is used to delete pro-angiogenic genes in endothelial cells or animal models to assess their necessity for angiogenesis. For example, knockout of OPN3 in HUVECs reduced VEGFR2 phosphorylation and tube formation, confirming its positive regulatory role. Knockout of Rap1 impairs endothelial cell migration and sprouting. These models provide causal evidence for gene function in angiogenesis.
Point Mutation
Point mutations can be introduced to dissect specific phosphorylation sites or functional domains of pro-angiogenic proteins. For instance, mutating key tyrosine residues in VEGFR2 can reveal their importance in downstream signaling. Point-mutation knock-in models are valuable for understanding how disease-associated variants affect angiogenesis.
Knock-in
Knock-in of tagged versions of pro-angiogenic proteins (e.g., GFP-OPN3) allows visualization and interaction studies in live cells. Knock-in of reporter genes under the control of pro-angiogenic promoters can be used to monitor angiogenesis in real time. These models are essential for tracking protein localization and dynamics during angiogenesis.
Overexpression
Overexpression of pro-angiogenic genes or microRNAs (e.g., miR-210) in endothelial cells or animal models can enhance angiogenesis and test sufficiency. Overexpression of sFlt-1, a negative regulator, can suppress angiogenesis, demonstrating the balance between positive and negative regulators. Overexpression models are useful for therapeutic angiogenesis studies.
How EDITGENE Supports positive regulation of angiogenesis Research
Researchers studying positive regulation of angiogenesis-related genes often need to determine whether a candidate gene is causally involved in endothelial cell proliferation, migration, or tube formation. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of pro-angiogenic genes and their regulatory networks.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of angiogenesis research.
Frequently Asked Questions About positive regulation of angiogenesis
What is positive regulation of angiogenesis (GO:0045766)?
It is any biological process that activates or increases angiogenesis, the formation of new blood vessels from pre-existing ones.
What genes are involved in positive regulation of angiogenesis?
Key genes include VEGFA, KDR (VEGFR2), OPN3, RAP1A, TP73, HIF1A, and microRNAs such as miR-210 and miR-126.
How is angiogenesis positively regulated?
Through pro-angiogenic growth factors like VEGF binding to receptors, activating intracellular signaling cascades that promote endothelial cell proliferation, migration, and tube formation.
What diseases involve dysregulated positive regulation of angiogenesis?
Cancer, cardiovascular disease, diabetic retinopathy, preeclampsia, and inflammatory disorders.
What is the role of VEGFR2 in angiogenesis?
VEGFR2 is the main receptor for VEGF; its activation triggers downstream signaling that drives endothelial cell activation and new vessel formation.
How do microRNAs regulate angiogenesis?
MicroRNAs such as miR-210 and miR-126 modulate angiogenesis by targeting pro- or anti-angiogenic factors at the post-transcriptional level.
What experimental models are used to study positive regulation of angiogenesis?
In vitro tube formation assays, in vivo Matrigel plug and zebrafish models, and CRISPR knockout/overexpression cell models.
Can CRISPR be used to study angiogenesis?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional dissection of pro-angiogenic genes.
What is the difference between positive and negative regulation of angiogenesis?
Positive regulation activates or increases angiogenesis, while negative regulation inhibits or decreases it; the balance determines net vessel growth.
How can I model positive regulation of angiogenesis in the lab?
Use endothelial cells (e.g., HUVECs) with CRISPR-mediated gene editing, combined with tube formation and migration assays.
Conclusion
Positive regulation of angiogenesis (GO:0045766) is a fundamental biological process that governs blood vessel formation in development, tissue repair, and disease. The interplay between pro-angiogenic factors such as VEGF and VEGFR2, intracellular signaling molecules like Rap1 and OPN3, and modulators such as microRNAs and HDL determines the angiogenic outcome. Dysregulation of this process contributes to cancer, cardiovascular disease, and other pathologies, making it a prime target for therapeutic intervention. Advances in CRISPR-based functional genomics and cell model engineering are accelerating the discovery of novel pro-angiogenic regulators and the development of targeted therapies. EDITGENE's comprehensive services support researchers in dissecting these mechanisms with precision and scale.
References
- 1. Luo H et al.. 2025. OPN3-mediated positive regulation of angiogenesis in HUVECs through VEGFR2 interaction.. Commun Biol 8(1):529 PMID: 40164822
- 2. Failla CM et al.. 2018. Positive and Negative Regulation of Angiogenesis by Soluble Vascular Endothelial Growth Factor Receptor-1.. Int J Mol Sci 19(5) PMID: 29702562
- 3. Fidler IJ. 2001. Regulation of neoplastic angiogenesis.. J Natl Cancer Inst Monogr PMID: 11158201
- 4. Hosseinpour S et al.. 2019. MicroRNAs Involved in the Regulation of Angiogenesis in Bone Regeneration.. Calcif Tissue Int 105(3):223-238 PMID: 31175386
- 5. Tan JT et al.. 2015. The role of high-density lipoproteins in the regulation of angiogenesis.. Cardiovasc Res 106(2):184-93 PMID: 25759067
- 6. Sabapathy K. 2015. p73: a Positive or Negative Regulator of Angiogenesis, or Both?. Mol Cell Biol 36(6):848-54 PMID: 26711266
- 7. Chrzanowska-Wodnicka M. 2010. Regulation of angiogenesis by a small GTPase Rap1.. Vascul Pharmacol 53(1-2):1-10 PMID: 20302970
- 8. Nakagawa K et al.. 2000. Angiogenesis and its regulation: roles of vascular endothelial cell growth factor.. Semin Thromb Hemost 26(1):61-6 PMID: 10805284
